Kronisk systolisk hjerteinsufficiens

Print kapitel

Referencer og litteratur

  1. Davies M, Hobbs F, Davies R et al. Prevalence of leftventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001;358:439-44.
  2. Petersen S, Rayner M, Wolstenholme J. Coronary heart disease statistics: heart failure supplement. London: British Heart Foundation, 2002.
  3. Cowie MR, Wood DA, Coats AJ et al. Incidence and aetiology of heart failure; a population- based study. European Heart Journal 1999;20:421-8.
  4. Udgår.
  5. McMurray J, McDonagh T, Morrison CE et al. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J 1993;14:1158-62.
  6. Cleland JG, Gemmell I, Khand A et al. Is the prognosis of heart failure improving? Eur J Heart Fail 1999;1: 229-41.
  7. Leidy NK, Rentz AM, Zyczynski TM. Evaluating healthrelated quality-of-life outcomes in patients with congestive heart failure. A review of recent randomised controlled trials. Pharmacoeconomics 1999;15:19-46.
  8. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. European Heart Journal 2001;22:1527-60.
  9. Ikram H. Identifying the patient with heart failure. Journal of International Medical Research 1995;23:139-53.
  10. Geltman EM. Mild heart failure: diagnosis and treatment. American Heart Journal 1989;118:1277-91.
  11. Davie AP, Francis CM, Caruana L et al. Assessing diagnosis in heart failure: which features are any use? Quarterly Journal of Medicine 1997; 90:335-9.
  12. Johnstone DE, Abdulla A, Arnold JM et al. Diagnosis and management of heart failure. Canadian Cardiovascular Society. Canadian Journal of Cardiology 1994;10: 613-31.
  13. Shamsham F, Mitchell J. Essentials of the diagnosis of heart failure. American Family Physician 2000;61:1319-28.
  14. Houghton AR, Sparrow NJ, Toms E et al. Should general practitioners use the electrocardiogram to select patients with suspected heart failure for echocardiography? International Journal of Cardiology1997;62:31-6.
  15. Knudsen CW, Westheim A, Omland T. B-type natriuretisk peptid i diagnostisering av hjertesvikt hos pasienter med akutt dyspné. Tidsskr Nor Lægeforen 2003,123:2045-8.
  16. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
  17. Jernberg T, Boman K, James S et al. BNP eller NT-proBNP bör analyseras vid mistänkt hjärtsvikt. Läkartidningen 2006;103:1289-95.
  18. Udgår
  19. Udgår
  20. http://www.kpll.dk/kpll/kpllnyt/kpll_nyt_1_2003.htm
  21. Senni M, Rodeheffer RJ, Tribouilloy CM et al. Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol. 1999;33:164-70.
  22. Ahmed A. American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice. J Am Geriatr Soc. 2003;51:123-6.
  23. Roelandt J, Lubsen J. Usefulness of quantitative echocardiography in congestive heart failure. Eur Heart J.1983;4:95-9.
  24. No authors listed. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983;309:331-6.
  25. Buser PT, Auffermann W, Holt WW et al. Noninvasive evaluation of global left ventricular function with use of cine nuclear magnetic resonance. J Am Coll Cardiol. 1989;13:1294-300.
  26. Semelka RC, Tomei E, Wagner S et al. Interstudy reproducibility of dimensional and functional measurements between cine magnetic resonance studies in the morphologically abnormal left ventricle. Am Heart J. 1990;119:1367-73.
  27. Bittner V, Weiner DH, Yusuf S et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA 1993; 270:1702-7.
  28. Rees K, Taylor RS, Singh S et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev. 2004;(3):CD003331.
  29. Piepoli MF, Davos C, Francis DP et al ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004;328: 189.
  30. Swedberg K, Cleland J, Dargie H et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-40.
  31. Azhar G, Wei JY. Nutrition and cardiac cachexia. Curr Opin Clin Nutr Metab Care. 2006; 9:18-23.
  32. Nicolás JM, Fernández-Solà J, Estruch R et al. The effect of controlled drinking in alcoholic cardiomyopathy. Ann Intern Med. 2002;136:192-200.
  33. Stein RA. Cardiovascular response to sexual activity. Am J Cardiol. 2000;86:27F-9F.
  34. Faris R, Flather MD, Purcell H et al. Diuretics for heart failure. Cochrane Database Syst Rev. 2006;(1):CD003838.
  35. Cowley AJ, Stainer K, Wynne RD et al. Symptomatic assessment of patients with heart failure: doubleblind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet. 1986;2:770-2.
  36. Køber L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670-6.
  37. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342: 821-8.
  38. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429-35.
  39. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992;327:685-91.
  40. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other bloodpressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000;356:1955-64.
  41. Flather MD, Yusuf S, Køber L et al. Long-term ACEinhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575-81.
  42. Lubsen J, Chadha DR, Yotof YT et al.Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure. Am J Cardiol. 1996;77:1191-6.
  43. Mancini GB. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations. Clin Invest Med. 2000;23:144-61.
  44. Beller B, Bulle T, Bourge RC et al. Lisinopril versus placebo in the treatment of heart failure: the Lisinopril Heart Failure Study Group. J Clin Pharmacol. 1995;35:673-80.
  45. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75.
  46. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.
  47. Pfeffer MA, Swedberg K, Granger CB et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-66.
  48. Jong P, Demers C, McKelvie RS. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2002;39:463-70.
  49. Granger CB, Ertl G, Kuch J et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000;139:609-17.
  50. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-7.
  51. Packer M, Coats AJ, Fowler MB et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heartfailure. N Engl J Med. 2001;344:1651-8.
  52. Flather MD, Shibata MC et. al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-25.
  53. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
  54. Bonet S, Agustí A, Arnau JM et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients’ characteristics: a meta-analysis of clinical trials. Arch Intern Med. 2000;160:621-7.
  55. Whorlow SL, Krum H. Meta-analysis of effect of betablocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. Am J Cardiol. 2000;86:886-9.
  56. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.
  57. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-51.
  58. Pitt B, Remme W, Zannad F et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348: 1309-21.
  59. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336:525-33.
  60. van Veldhuisen DJ, Man in ‘t Veld AJ, Dunselman PH, Lok DJ, Dohmen HJ, Poortermans JC, Withagen AJ, Pasteuning WH, Brouwer J, Lie KI. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol. 1993; 22:1564-73.
  61. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993;22:955-62. 
  62. McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs R, Maggioni A, Pina I, Soler-Soler J, Swedberg K. Clinical Research Initiative in Heart failure. Practical recommendations for the use of ACE inhibitors, betablockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail. 2001;3:495-502.
  63. Kjekshus J, Pedersen TR, Olsson AG et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3:249-54.
  64. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
  65. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol. 2002;39:1567-73.
  66. Feenstra J, Heerdink ER, Grobbee DE et al. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med. 2002;162:265-70.
  67. Gislason GH, Jacobsen S, Rasmussen JN et al. Risk of death or reinfarction associated with theuse of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906-13.
  68. Stewart S, MacIntyre K, Hole DJ et al. More ‘malignant’ than cancer? Five-year urvival following a first admission for heart failure. Eur J Heart Fail. 2001;3:315-22.
  69. Böhm M, Swedberg K, Komajda M et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886-94.
  70. Mulder P, Barbier S, Chagraoui A et al. Long-term heart ate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109:1674-9.
  71. Rector TS, Johnson G, Dunkman WB et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI71-7.
     

Litteratur

  • Allen LA, Yager JE, Funk MJ et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA. 2008;299:2533-42.
  • Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-52
  • Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-7.
  • Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
  • Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet. 1997;350:1417-24.
  • Hartmann F, Packer M, Coats AJ et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Circulation 2004;110:1780-6.
  • Køber L, Bloch Thomsen PE, Møller M et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet. 2000;356:2052-8.
  • McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: β-Blokker Dose, Heart Reduction, and Death in Patients With Heart Failure. Ann Intern Med 2009;150:784-94.
  • O’Connor CM, Starling RC, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43.
  • Oliva F, Latini R, Politi A et al. Intermittent 6-month lowdose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J. 1999;138:247-53. 
  • Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
  • Packer M, Narahara KA, Elkayam U et al. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. J Am Coll Cardiol. 1993;22:65-72.
  • Piepoli M, Villani GQ, Ponikowski P et al. Overview and metaanalysis of randomised trials of amiodarone in chronic heart failure. Int J Cardiol. 1998;66:1-10.
  • Schou M, Gustafsson F, Corell P et al. The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure. Am Heart J. 2007;154:123-9.
  • Torp-Pedersen C, Møller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341:857-65.
  • WHO. Adherence to long-term therapies. Evidence for action. World Healht Organisation 2003.
  • Zannad F, McMurray JJV, Krum H, Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2010 Nov 14. [Epub ahead of print].